Michael Mann

Dr. Michael Mann

H. Lee Moffitt Cancer Center and Research Institute
+1
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Michael MannMichael Mann
Michael Mann
HYHaoqiang Ying
Haoqiang Ying
JJJoseph Juan
Joseph Juan
NJNancy A. Jenkins
Nancy A. Jenkins
NCNeal G. Copeland
Neal G. Copeland

27 January 2005 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
Michael MannMichael Mann
Michael Mann
CHCraig A. Hodges
Craig A. Hodges
EBEllen Barnes
Ellen Barnes
HVHannes Vogel
Hannes Vogel
THTerry J. Hassold
Terry J. Hassold
GLGuangbin Luo
Guangbin Luo
Type II Rothmund–Thomson syndrome (Type II RTS) is a rare autosomal recessive genetic disorder characterized by a congenital skin rash, birth defects of the skeleton, genomic instability and cancer predisposition. It is caused by mutations in the RECQL4 gene and thus represents one of the three cancer-prone genetic diseases that are caused by mutations in a RecQ helicase-encoding gene. Genomic instability has been suspected as a major underlying cause of this disease, and analyses of Type II RTS patient-derived cells demonstrate unusually high frequencies of chromosomal aberrations, suggesting the involvement of chromosomal instability. However, the nature of the instability induced by RECQL4 mutations has not been clearly defined. We created a viable Recql4 mutant mouse model. These mice exhibit a distinctive skin abnormality, birth defects of the skeletal system, genomic instability and increased cancer susceptibility in a sensitized genetic background. Thus, they provide a useful model for studying Type II RTS. In addition, we demonstrate that cells from these mutant mice have high frequencies of premature centromere separation and aneuploidy. Thus, our observations provide evidence for a previously unsuspected role for Recql4 in sister-chromatid cohesion, and suggest that the chromosomal instability may be the underlying cause of cancer predisposition and birth defects in these mutant mice.

5 January 2015 in Nature Genetics
Verified
Journal Article
Closed access
HTHaruna Takeda
Haruna Takeda
ZWZhubo Wei
Zhubo Wei
HKHideto Koso
Hideto Koso
ARAlistair G Rust
Alistair G Rust
CYChristopher Chin Kuan Yew
Christopher Chin Kuan Yew
NJNancy A Jenkins
Nancy A Jenkins

13 April 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
Michael MannMichael Mann
Michael Mann
MBMichael Black
Michael Black
DJDevin J Jones
Devin J Jones
JWJerrold M Ward
Jerrold M Ward
CYChristopher Chin Kuan Yew
Christopher Chin Kuan Yew
NJNancy A Jenkins
Nancy A Jenkins

14 November 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RRRoberto Rangel
Roberto Rangel
SLSong-Choon Lee
Song-Choon Lee
KBKenneth Hon-Kim Ban
Kenneth Hon-Kim Ban
LGLiliana Guzman-Rojas
Liliana Guzman-Rojas
Michael MannMichael Mann
Michael Mann
NCNeal G. Copeland
Neal G. Copeland
Significance: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Despite extensive cancer genome-sequencing efforts, there is still an incomplete understanding of the genetic networks driving TNBC. Here, we usedSleeping Beautytransposon mutagenesis to identify genes that cooperate with mutantPtenin the induction of TNBC. We identified 12 candidate TNBC trunk drivers and a larger number of progression genes. Subsequent functional validation studies identified eight human TNBC tumor suppressor genes, including the GATA-like transcriptional repressorTRPS1, which was shown to inhibit lung metastasis by deregulating the expression of multiple serpin and epithelial-to-mesenchymal transition (EMT) pathway genes. Our study provides a better understanding of the genetic forces driving TNBC and discovered genes with clinical importance in TNBC.

1 August 2016 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
KMKaren M Mann
Karen M Mann
JNJustin Y Newberg
Justin Y Newberg
MBMichael Black
Michael Black
DJDevin J Jones
Devin J Jones
FAFelipe Amaya-Manzanares
Felipe Amaya-Manzanares
Michael MannMichael Mann
Michael Mann
Oncogenic driver mutations are identified in single cells by a transposon-based sequencing method. A central challenge in oncology is how to kill tumors containing heterogeneous cell populations defined by different combinations of mutated genes. Identifying these mutated genes and understanding how they cooperate requires single-cell analysis, but current single-cell analytic methods, such as PCR-based strategies or whole-exome sequencing, are biased, lack sequencing depth or are cost prohibitive. Transposon-based mutagenesis allows the identification of early cancer drivers, but current sequencing methods have limitations that prevent single-cell analysis. We report a liquid-phase, capture-based sequencing and bioinformatics pipeline, Sleeping Beauty (SB) capture hybridization sequencing (SBCapSeq), that facilitates sequencing of transposon insertion sites from single tumor cells in a SB mouse model of myeloid leukemia (ML). SBCapSeq analysis of just 26 cells from one tumor revealed the tumor's major clonal subpopulations, enabled detection of clonal insertion events not detected by other sequencing methods and led to the identification of dominant subclones, each containing a unique pair of interacting gene drivers along with three to six cooperating cancer genes with SB-driven expression changes.